Biotech Values

[dewophile]

It's odd to not include the control arms for sure
OTOH on a none or mild endpoint they did show 6 months duration (surprisingly). However I do find it odd that the duration on this (more appropriate) endpoint is no different than the 1-point improvement on the GLS scale which was identical - i.e. there were minimal to no patients who had a 1-point improvement from baseline of 3 to 2 everyone who started at 3 seemed to go to 0 or 1 when the effects started to wear off. You can easily see this if the interval between visits is very long and then you can easily miss the time points when efficacy gradually goes from baseline of 3 to 2 to 0/1 (non/mild)
so somewhat weird data. Here's hoping the 6 month duration on non-mild w reasonable AE profile doesn't hold up